Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial
Age and Ageing · 2024
DOI: 10.1093/ageing/afae132 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, 2024. Verfasst von Seung-Jun Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Artery Disease, Cholesterol, LDL. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
The optimal statin treatment strategy that is balanced for both efficacy and safety has not been clearly determined in older adults with coronary artery disease (CAD).
Methods
In the post hoc analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting statin therapy versus intensity-based statin therapy in patients with coronary artery disease) trial, the impact between a treat-to-target strategy versus a high-intensity statin therapy strategy was compared in older adults (aged 75 years or older). The goal of treat-to-target low-density lipoprotein cholesterol (LDL-C) level was 50–70 mg/dl. The primary endpoint comprised the three-year composite of all-cause death, myocardial infarction, stroke or coronary revascularisation.
Results
Among 4,400 patients with CAD enrolled in the LODESTAR trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and risk factors for atherosclerosis were more frequently observed in older adults than in younger population (<75 years old). Among these older adults with CAD, the prescription rate of high-intensity statin was significantly lower in the treat-to-target strategy group throughout the study period (P < 0.001). The mean LDL-C level for three years was 65 ± 16 mg/dl in the treat-to-target strategy group and 64 ± 18 mg/dl in the high-intensity statin group (P = 0.34). The incidence of primary endpoint occurrence was 10.9% in the treat-to-target strategy group and 12.0% in the high-intensity statin group (hazard ratio 0.92, 95% confidence interval 0.61–1.38, P = 0.69).
Conclusions
High-intensity statin therapy is theoretically more necessary in older adults because of worse clinical outcomes and greater number of risk factors for atherosclerosis. However, the primary endpoint occurrence with a treat-to-target strategy with an LDL-C goal of 50–70 mg/dl was comparable to that of high-intensity statin therapy and reduced utilisation of a high-intensity statin. Taking efficacy as well as safety into account, adopting a tailored approach may be considered for this high-risk population. Trial Registration ClinicalTrials.gov, NCT02579499.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Korea.
- Daegu Catholic University Medical Center, Duryugongwon-ro 17-gil, Nam-gu, 42472, Daegu, Korea.
- Inje University Busan Paik Hospital, Bokji-ro 75, Busanjin-gu, 47392, Busan, Korea.
- Gachon University College of Medicine, Namdong-daero 774 beon-gil, Namdong-gu, 21565, Incheon, Korea.
- Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Saemunan-ro, Jongno-gu, 03181, Seoul, Korea.
- Gangnam Severance Hospital, Eonju-ro, Gangnam-gu, 06273, Seoul, Korea.
Zitieren
APA
Lee, S. J., Lee, J. B., Yang, T. H., Kang, W. C., Lee, J. Y., Lee, Y. J., Hong, S. J., Ahn, C. M., Kim, J. S., Kim, B. K., Ko, Y. G., Hong, B. K., Choi, D., Yoon, J., Jang, Y., Hong, M. K., & LODESTAR investigators (2024). Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial. Age and Ageing. https://doi.org/10.1093/ageing/afae132
Vancouver
Lee SJ, Lee JB, Yang TH, Kang WC, Lee JY, Lee YJ, et al. Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial. Age and Ageing. 2024. doi:10.1093/ageing/afae132
BibTeX
@article{Lee2024,
author = {Lee, Seung-Jun and Lee, Jin-Bae and Yang, Tae-Hyun and Kang, Woong Chol and Lee, Jong-Young and Lee, Yong-Joon and Hong, Sung-Jin and Ahn, Chul-Min and Kim, Jung-Sun and Kim, Byeong-Keuk and Ko, Young-Guk and Hong, Bum-Kee and Choi, Donghoon and Yoon, Junghan and Jang, Yangsoo and Hong, Myeong-Ki and LODESTAR investigators, LODESTAR investigators},
title = {Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial},
journal = {Age and Ageing},
year = {2024},
doi = {10.1093/ageing/afae132}
}
EUVIMED